BRPI0410129B8 - anticorpo anti-cs1 isolado, fragmento de ligação de antígeno, composto conjugado e composição farmacêutica - Google Patents

anticorpo anti-cs1 isolado, fragmento de ligação de antígeno, composto conjugado e composição farmacêutica

Info

Publication number
BRPI0410129B8
BRPI0410129B8 BRPI0410129A BRPI0410129A BRPI0410129B8 BR PI0410129 B8 BRPI0410129 B8 BR PI0410129B8 BR PI0410129 A BRPI0410129 A BR PI0410129A BR PI0410129 A BRPI0410129 A BR PI0410129A BR PI0410129 B8 BRPI0410129 B8 BR PI0410129B8
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
antigen binding
antibody
binding fragment
isolated anti
Prior art date
Application number
BRPI0410129A
Other languages
English (en)
Inventor
Yun Tso J
Williams Marna
F Landolfi Nicholas
Original Assignee
Abbott Biotherapeutics Corp
Abbvie Biotherapeutics Inc
Facet Biotech Corp
Pdl Biopharma Inc
Protein Design Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Biotherapeutics Corp, Abbvie Biotherapeutics Inc, Facet Biotech Corp, Pdl Biopharma Inc, Protein Design Labs Inc filed Critical Abbott Biotherapeutics Corp
Publication of BRPI0410129A publication Critical patent/BRPI0410129A/pt
Publication of BRPI0410129B1 publication Critical patent/BRPI0410129B1/pt
Publication of BRPI0410129B8 publication Critical patent/BRPI0410129B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70507—CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Glass Compositions (AREA)
  • Luminescent Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

uso terapêutico de anticorpos anti-cs1. a presente invenção é direcionada a antagonistas de cs1 que ligam-se a e neutralizam pelo menos uma atividade biológica de cs1. a invenção também inclui uma composição farmacêutica compreendendo tais anticorpos ou fragmentos de ligação de antígeno destes. a presente invenção também fornece um método de prevenir ou tratar condições de doença, incluindo câncer e distúrbios auto-imunes, em um indivíduo com necessidade deste, compreendendo administrar ao referido indivíduo uma quantidade eficaz de tais antagonistas.
BRPI0410129A 2003-05-08 2004-05-10 anticorpo anti-cs1 isolado, fragmento de ligação de antígeno, composto conjugado e composição farmacêutica BRPI0410129B8 (pt)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US46921103P 2003-05-08 2003-05-08
US60/469,211 2003-05-08
US55762104P 2004-03-29 2004-03-29
US55762204P 2004-03-29 2004-03-29
US55762004P 2004-03-29 2004-03-29
US60/557,622 2004-03-29
US60/557,620 2004-03-29
US60/557,621 2004-03-29
PCT/US2004/014866 WO2004100898A2 (en) 2003-05-08 2004-05-10 Therapeutic use of anti-cs1 antibodies

Publications (3)

Publication Number Publication Date
BRPI0410129A BRPI0410129A (pt) 2006-05-16
BRPI0410129B1 BRPI0410129B1 (pt) 2020-02-11
BRPI0410129B8 true BRPI0410129B8 (pt) 2021-05-25

Family

ID=33459144

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410129A BRPI0410129B8 (pt) 2003-05-08 2004-05-10 anticorpo anti-cs1 isolado, fragmento de ligação de antígeno, composto conjugado e composição farmacêutica

Country Status (25)

Country Link
US (8) US20050025763A1 (pt)
EP (4) EP2371391B1 (pt)
JP (4) JP4887152B2 (pt)
KR (1) KR101268707B1 (pt)
CN (1) CN1805755B (pt)
AT (1) ATE506076T1 (pt)
AU (2) AU2004238363B2 (pt)
BE (1) BE2016C056I2 (pt)
BR (1) BRPI0410129B8 (pt)
CA (1) CA2523001C (pt)
CY (4) CY1111958T1 (pt)
DE (1) DE602004032328D1 (pt)
DK (3) DK2371391T3 (pt)
ES (2) ES2516840T3 (pt)
FR (1) FR16C1012I2 (pt)
HK (3) HK1089374A1 (pt)
HU (2) HUE034908T2 (pt)
LT (1) LT2853272T (pt)
LU (1) LU93274I2 (pt)
MX (1) MXPA05012011A (pt)
NL (1) NL300838I2 (pt)
PL (3) PL2853272T3 (pt)
PT (3) PT2853272T (pt)
SI (3) SI2371391T1 (pt)
WO (1) WO2004100898A2 (pt)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20080095768A1 (en) * 2006-08-07 2008-04-24 Pdl Biopharma, Inc. Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells
EP2068930B1 (en) * 2006-08-07 2012-09-19 Abbott Biotherapeutics Corp. Compositions and methods using anti-cs1 antibodies to treat multiple myeloma
NZ574978A (en) 2006-08-07 2012-08-31 Dana Farber Cancer Inst Inc Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies
JP2011523560A (ja) * 2008-06-02 2011-08-18 ダナ−ファーバー キャンサー インスティテュート インク． Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド
CN102216332A (zh) * 2008-10-31 2011-10-12 艾伯特生物治疗学公司 抗-cs1抗体用于治疗罕见淋巴瘤的用途
EP2382321A4 (en) * 2009-01-08 2012-12-19 Bio Rad Laboratories METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY OF NUCLEIC ACID AMPLIFICATION REACTIONS
CA2779683A1 (en) * 2009-11-10 2011-05-19 Amgen Inc. Anti-c-mpl antibodies
JP5850860B2 (ja) 2010-01-28 2016-02-03 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｃｄ１２７結合タンパク質
KR20220017432A (ko) 2010-02-24 2022-02-11 이뮤노젠 아이엔씨 엽산염 수용체 1 항체와 면역접합체 및 이들의 용도
MX346555B (es) 2011-04-01 2017-03-24 Immunogen Inc Metodos para aumentar la eficacia de la terapia contra el cancer con receptor 1 de folato (folr1).
PL2890717T3 (pl) 2012-08-31 2020-08-10 Immunogen, Inc. Testy i zestawy diagnostyczne do wykrywania receptora folianu
JP6374392B2 (ja) 2012-11-05 2018-08-15 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｘｂｐ１、ｃｄ１３８およびｃｓ１ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法
CN105377892A (zh) * 2013-03-15 2016-03-02 艾伯维生物技术有限公司 抗cd25抗体及其用途
JP6449229B2 (ja) * 2013-03-15 2019-01-09 アッヴィ・バイオセラピューティクス・インコーポレイテッド Ｆｃ変異体
CA2910666A1 (en) * 2013-05-03 2014-11-06 Ohio State Innovation Foundation Cs1-specific chimeric antigen receptor engineered immune effector cells
WO2015013508A2 (en) * 2013-07-24 2015-01-29 The General Hospital Corporation Methods for diagnosing and treating immune disease
WO2015031815A2 (en) 2013-08-30 2015-03-05 Immunogen, Inc. Antibodies and assays for detection of folate receptor 1
US9482289B2 (en) 2013-10-14 2016-11-01 Club Car, Llc Self-preloading shift lever
EP3066127A1 (en) 2013-11-06 2016-09-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
ES2707057T3 (es) 2013-11-06 2019-04-02 Bristol Myers Squibb Co Combinación de anticuerpos anti-KIR y anti-CS1 para tratar el mieloma múltiple
US20170051037A1 (en) * 2014-05-02 2017-02-23 Cellectis Cs1 specific multi-chain chimeric antigen receptor
JP2017522289A (ja) * 2014-06-17 2017-08-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 改善されたα−Ｖβ−８抗体
MA40253A (fr) 2014-07-15 2017-05-24 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
WO2016049022A1 (en) * 2014-09-23 2016-03-31 Board Of Trustees Of Michigan State University Compositions and methods for modulating an immune response
ES2832711T3 (es) * 2014-10-31 2021-06-11 Abbvie Biotherapeutics Inc Anticuerpos anti-CS1 y conjugados anticuerpo fármaco
BR112017011538A2 (pt) 2014-12-04 2018-03-13 Bristol-Myers Squibb Company combinação de anticorpos anti-cs1 e anti-pd1 para tratar câncer (mieloma)
DE102015102183B4 (de) * 2015-02-16 2018-03-01 Robert Bosch Automotive Steering Gmbh Lenkzwischenwelle für ein Kraftfahrzeug und Verfahren zum Betreiben einer Lenkzwischenwelle für ein Kraftfahrzeug
CA2977350C (en) 2015-02-20 2022-08-23 Ohio State Innovation Foundation Bivalent antibody directed against nkg2d and tumor associated antigens
US20180100026A1 (en) * 2015-04-15 2018-04-12 California Institute For Biomedical Research Optimized chimeric receptor t cell switches and uses thereof
CN107949425A (zh) 2015-06-29 2018-04-20 百时美施贵宝公司 用于治疗癌症的包含泊马度胺和抗cs1抗体的免疫治疗给药方案
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
WO2017049149A1 (en) 2015-09-17 2017-03-23 Immunogen, Inc. Therapeutic combinations comprising anti-folr1 immunoconjugates
MA43186B1 (fr) 2015-11-03 2022-03-31 Janssen Biotech Inc Anticorps se liant spécifiquement à pd-1 et leurs utilisations
WO2018169999A1 (en) 2017-03-13 2018-09-20 Intrinsic Lifesciences Llc Antibodies to human erythroferrone and uses thereof
EP3601365A4 (en) * 2017-03-29 2021-01-13 Agency for Science, Technology and Research ANTI-OLIGOSACCHARIDE ANTIBODIES
MX2019015841A (es) 2017-06-20 2020-08-03 Inst Curie Celulas inmunes defectuosas para suv39h1.
SG11202000846WA (en) * 2017-08-07 2020-02-27 Nbe Therapeutics Ag Anthracycline-based antibody drug conjugates having high in vivo tolerability
US20210254000A1 (en) 2017-11-01 2021-08-19 Juno Therapeutics, Inc. Process for producing a t cell composition
BR112020008323A2 (pt) 2017-11-01 2020-11-03 Juno Therapeutics Inc anticorpos e receptores de antígenos quiméricos específicos para antígeno de maturação de células b
CN111542596A (zh) 2017-11-01 2020-08-14 朱诺治疗学股份有限公司 产生工程化细胞的治疗性组合物的方法
US11564946B2 (en) 2017-11-01 2023-01-31 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
CA3082010A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Chimeric antigen receptors specific for b-cell maturation antigen (bcma)
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
AU2018379091A1 (en) 2017-12-08 2020-06-25 Juno Therapeutics, Inc. Serum-free media formulation for culturing cells and methods of use thereof
CN112203680A (zh) 2017-12-08 2021-01-08 朱诺治疗学股份有限公司 用于细胞疗法的表型标记和相关方法
BR112020011215A2 (pt) 2017-12-08 2020-11-17 Juno Therapeutics Inc processo para a produção de uma composição de células t modificadas
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
TW201946654A (zh) 2018-03-05 2019-12-16 比利時商健生藥品公司 抗ＰＨＦ－Ｔａｕ抗體及其用途
US11629179B2 (en) 2018-06-29 2023-04-18 Stichting Het Nederlands Kanker Instituut—Antoni van Leeuwenhoek Ziekenhuis TWEAK-receptor agonists for use in combination with immunotherapy of a cancer
MX2021001519A (es) 2018-08-09 2021-05-27 Juno Therapeutics Inc Metodos para valorar acidos nucleicos integrados.
CN109406798A (zh) * 2018-10-29 2019-03-01 美康生物科技股份有限公司 肌酐酶法检测试剂盒
AU2019374103A1 (en) 2018-11-01 2021-05-20 Juno Therapeutics, Inc. Chimeric antigen receptors specific for G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)
CN113646335A (zh) 2018-11-01 2021-11-12 朱诺治疗学股份有限公司 使用对b细胞成熟抗原具有特异性的嵌合抗原受体的治疗的方法
IL263394A (en) * 2018-11-29 2020-05-31 Amit Ido Methods for activating inactive immune cells and cancer treatment
WO2020223571A1 (en) 2019-05-01 2020-11-05 Juno Therapeutics, Inc. Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
AU2020265741A1 (en) 2019-05-01 2021-11-25 Editas Medicine, Inc. Cells expressing a recombinant receptor from a modified TGFBR2 Locus, related polynucleotides and methods
KR20220042161A (ko) 2019-07-23 2022-04-04 엥스띠뛰 퀴리 Suv39h1에 결함이 있는 면역 세포
WO2021092044A1 (en) 2019-11-05 2021-05-14 Bristol-Myers Squibb Company M-protein assays and uses thereof
EP4100062A4 (en) * 2020-02-05 2024-05-22 Navaux, Inc. ANTI-HEPSIN ANTIBODIES AND USES THEREOF
KR20230009386A (ko) 2020-04-10 2023-01-17 주노 쎄러퓨티크스 인코퍼레이티드 Ｂ-세포 성숙 항원을 표적화하는 키메라 항원 수용체로 조작된 세포 요법 관련 방법 및 용도
EP4150640A1 (en) 2020-05-13 2023-03-22 Juno Therapeutics, Inc. Methods of identifying features associated with clinical response and uses thereof
KR20230042283A (ko) 2020-06-26 2023-03-28 주노 테라퓨틱스 게엠베하 재조합 수용체를 조건부로 발현하는 조작된 ｔ 세포, 관련된 폴리뉴클레오티드 및 방법
US20230303974A1 (en) 2020-07-30 2023-09-28 Institut Curie Immune Cells Defective for SOCS1
WO2022098787A1 (en) 2020-11-04 2022-05-12 Juno Therapeutics, Inc. Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
JP2024509853A (ja) 2021-03-03 2024-03-05 ジュノー セラピューティクス インコーポレイテッド Ｔ細胞療法およびｄｇｋ阻害剤の組合せ
WO2022234009A2 (en) 2021-05-06 2022-11-10 Juno Therapeutics Gmbh Methods for stimulating and transducing t cells
WO2022238386A1 (en) 2021-05-10 2022-11-17 Institut Curie Methods for the treatment of cancer, inflammatory diseases and autoimmune diseases
EP4346912A1 (en) 2021-05-25 2024-04-10 Institut Curie Myeloid cells overexpressing bcl2
WO2023126458A1 (en) 2021-12-28 2023-07-06 Mnemo Therapeutics Immune cells with inactivated suv39h1 and modified tcr
WO2023147515A1 (en) 2022-01-28 2023-08-03 Juno Therapeutics, Inc. Methods of manufacturing cellular compositions
WO2023159182A1 (en) 2022-02-18 2023-08-24 Rakuten Medical, Inc. Anti-programmed death-ligand 1 (pd-l1) antibody molecules, encoding polynucleotides, and methods of use
WO2023187024A1 (en) 2022-03-31 2023-10-05 Institut Curie Modified rela protein for inducing interferon expression and engineered immune cells with improved interferon expression
WO2023213969A1 (en) 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023230581A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Methods of manufacturing t cell therapies
WO2023230548A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Method for predicting response to a t cell therapy
WO2024054944A1 (en) 2022-09-08 2024-03-14 Juno Therapeutics, Inc. Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
WO2024100604A1 (en) 2022-11-09 2024-05-16 Juno Therapeutics Gmbh Methods for manufacturing engineered immune cells
WO2024114691A1 (en) * 2022-12-02 2024-06-06 Guangzhou Litai Biotechnology Co., Ltd. Human cs1 car-t cells
WO2024124132A1 (en) 2022-12-09 2024-06-13 Juno Therapeutics, Inc. Machine learning methods for predicting cell phenotype using holographic imaging

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5004692A (en) 1987-12-15 1991-04-02 Protein Design Labs, Inc. Cloning and expression of phosopholipase C genes
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US6329508B1 (en) 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
KR0162259B1 (ko) 1989-12-05 1998-12-01 아미 펙터 감염성 병변 및 염증성 병변을 검출 및 치료하기 위한 키메라 항체
US20020099179A1 (en) * 1989-12-21 2002-07-25 Linda K. Jolliffe Cdr-grafted antibodies
AU633698B2 (en) 1990-01-12 1993-02-04 Amgen Fremont Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5386023A (en) 1990-07-27 1995-01-31 Isis Pharmaceuticals Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
US5644048A (en) 1992-01-10 1997-07-01 Isis Pharmaceuticals, Inc. Process for preparing phosphorothioate oligonucleotides
JPH07101999A (ja) * 1993-10-06 1995-04-18 Hagiwara Yoshihide 抗癌ヒトモノクローナル抗体に対する抗イデイオタイプ抗体のアミノ酸配列およびそれをコードするｄｎａ塩基配列
US5637684A (en) 1994-02-23 1997-06-10 Isis Pharmaceuticals, Inc. Phosphoramidate and phosphorothioamidate oligomeric compounds
US6015880A (en) 1994-03-16 2000-01-18 California Institute Of Technology Method and substrate for performing multiple sequential reactions on a matrix
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
WO1996039518A1 (en) 1995-06-05 1996-12-12 Bionebraska, Inc. Lead binding polypeptides and nucleotides coding therefor
US6607898B1 (en) * 1996-03-26 2003-08-19 Oncomedx, Inc. Method for detection of hTR and hTERT telomerase-associated RNA in plasma or serum
WO2000047602A1 (en) 1999-02-10 2000-08-17 Human Genome Sciences, Inc. 33 human secreted proteins
CA2284550A1 (en) * 1997-03-21 1998-10-01 Human Genome Sciences, Inc. 87 human secreted proteins
IL139686A0 (en) 1998-06-02 2002-02-10 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000011150A1 (en) 1998-08-25 2000-03-02 Incyte Pharmaceuticals, Inc. Cell surface immunomodulators
CA2296792A1 (en) 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
US7465785B2 (en) * 1999-03-08 2008-12-16 Genentech, Inc. Polypeptide encoded by a nucleic acid over-expressed in melanoma
WO2000055627A1 (en) 1999-03-15 2000-09-21 Eos Biotechnology, Inc. Reusable low fluorescent plastic biochip
AU3774300A (en) 1999-06-02 2000-12-18 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1208202A2 (en) 1999-09-01 2002-05-29 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2001046260A2 (en) * 1999-12-23 2001-06-28 Bristol-Myers Squibb Company Novel immunoglobulin superfamily members apex-1, apex-2 and apex-3 and uses thereof
AU6802801A (en) 2000-03-01 2001-09-24 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2001260153B2 (en) * 2000-03-24 2006-08-17 Micromet Ag Multifunctional polypeptides comprising a binding site to an epitope of the NKG2D receptor complex
EP1283721A4 (en) 2000-05-26 2004-07-07 Smithkline Beecham Corp ANTI-RANK-LIGAND-BINDING MONOCLONAL ANTIBODIES USEFUL FOR TREATING DISEASES CAUSED BY THE RANK-LIGANDS
US6410271B1 (en) 2000-06-23 2002-06-25 Genetastix Corporation Generation of highly diverse library of expression vectors via homologous recombination in yeast
BR0206985A (pt) * 2001-01-29 2005-04-19 Idec Pharma Corp Anticorpos modificados e métodos de uso
CA2441832A1 (en) 2001-03-21 2002-12-27 Human Genome Sciences, Inc. Human secreted proteins
US20030099974A1 (en) * 2001-07-18 2003-05-29 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer
WO2003018621A2 (en) 2001-08-23 2003-03-06 Oxford Biomedica (Uk) Limited Genes
US20040038877A1 (en) 2001-10-02 2004-02-26 Alsobrook John P. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US6478825B1 (en) * 2001-11-28 2002-11-12 Osteotech, Inc. Implant, method of making same and use of the implant for the treatment of bone defects
US7041499B2 (en) * 2001-12-12 2006-05-09 University Of North Texas Health Science Center Immuno activation of CS1 receptor in natural killer cells to inhibit tumor cell growth
DK2345671T3 (en) 2002-09-27 2016-02-15 Xencor Inc Optimized Fc variants and methods for their formation
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
US7709610B2 (en) * 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
CN102216332A (zh) 2008-10-31 2011-10-12 艾伯特生物治疗学公司 抗-cs1抗体用于治疗罕见淋巴瘤的用途
WO2013037693A2 (de) 2011-09-15 2013-03-21 Convergent Information Technologies Gmbh System und verfahren zur automatisierten erstellung von roboterprogrammen
US9505153B2 (en) 2012-02-13 2016-11-29 Radius Engineering, Inc. Reusable cartridge for injection molding

Also Published As

Publication number Publication date
PT2371391E (pt) 2014-10-30
SI1624892T1 (sl) 2011-08-31
US8008450B2 (en) 2011-08-30
AU2010214661B2 (en) 2012-05-17
CY1119353T1 (el) 2018-02-14
JP2017019795A (ja) 2017-01-26
BRPI0410129B1 (pt) 2020-02-11
SI2853272T1 (sl) 2017-10-30
EP1624892B1 (en) 2011-04-20
AU2010214661A1 (en) 2010-09-16
CN1805755B (zh) 2011-06-01
US20120064083A1 (en) 2012-03-15
DE602004032328D1 (de) 2011-06-01
JP2014139187A (ja) 2014-07-31
EP2853272B1 (en) 2017-08-02
CA2523001A1 (en) 2004-11-25
US9175081B2 (en) 2015-11-03
JP6042834B2 (ja) 2016-12-14
US8133981B2 (en) 2012-03-13
DK2853272T3 (da) 2017-11-06
FR16C1012I2 (fr) 2019-01-11
KR101268707B1 (ko) 2013-05-29
HUS1600042I1 (hu) 2016-11-28
BE2016C056I2 (pt) 2023-08-09
LU93274I2 (fr) 2016-12-27
JP5976288B2 (ja) 2016-08-23
US20090238827A1 (en) 2009-09-24
DK2371391T3 (da) 2014-11-03
EP1624892A2 (en) 2006-02-15
WO2004100898A2 (en) 2004-11-25
US20200031929A1 (en) 2020-01-30
CN1805755A (zh) 2006-07-19
HK1208815A1 (en) 2016-03-18
US20140065063A1 (en) 2014-03-06
KR20060018837A (ko) 2006-03-02
AU2004238363A1 (en) 2004-11-25
DK1624892T3 (da) 2011-08-08
CY1111958T1 (el) 2015-11-04
US10442859B2 (en) 2019-10-15
EP2853272A1 (en) 2015-04-01
EP3275463A1 (en) 2018-01-31
US20090238835A1 (en) 2009-09-24
US20100168397A1 (en) 2010-07-01
LT2853272T (lt) 2017-10-10
MXPA05012011A (es) 2006-02-03
SI2371391T1 (sl) 2014-12-31
EP2371391B1 (en) 2014-07-23
CY2016035I1 (el) 2017-09-13
ATE506076T1 (de) 2011-05-15
ES2643289T3 (es) 2017-11-22
US20050025763A1 (en) 2005-02-03
PL2853272T3 (pl) 2018-01-31
PT1624892E (pt) 2011-07-12
BRPI0410129A (pt) 2006-05-16
AU2004238363B2 (en) 2010-05-27
WO2004100898A3 (en) 2005-08-18
JP4887152B2 (ja) 2012-02-29
HK1089374A1 (en) 2006-12-01
CA2523001C (en) 2013-12-31
FR16C1012I1 (pt) 2016-09-12
PL2371391T3 (pl) 2015-01-30
CY2016035I2 (el) 2017-09-13
EP2371391A1 (en) 2011-10-05
HK1163497A1 (en) 2012-09-14
NL300838I2 (pt) 2017-01-03
US20160002335A1 (en) 2016-01-07
CY1115671T1 (el) 2017-01-25
HUE034908T2 (hu) 2018-03-28
PT2853272T (pt) 2017-08-30
US8445646B2 (en) 2013-05-21
PL1624892T3 (pl) 2011-09-30
JP2012121878A (ja) 2012-06-28
ES2516840T3 (es) 2014-10-31
EP1624892A4 (en) 2007-08-08
JP2007503465A (ja) 2007-02-22

Similar Documents

Publication Publication Date Title
BRPI0410129B8 (pt) anticorpo anti-cs1 isolado, fragmento de ligação de antígeno, composto conjugado e composição farmacêutica
BRPI0418695A (pt) uso terapêutico de anticorpos anti-cs1
KR101155294B1 (ko) 면역특이적으로 ＢＬｙＳ에 결합하는 항체
BRPI0622073A8 (pt) Uso de anticorpos pdgfralfa para fabricação de um medicamento para tratar um tumor ósseo
BRPI0412890B8 (pt) método de selecionar um anticorpo anti kir2dl1 ou fragmento de anticorpo de ligação de antígeno
WO2005120557A3 (en) Inhibition of macrophage-stimulating protein receptor (ron)
NO982062L (no) Humaniserte antistoff mot humant gp39, sammensetninger inneholdende dette, samt terapeutisk anvendelse derav
EP1401870A4 (en) ANTIBODIES AGAINST TUMOR NECROSIS FACTOR DELTA (APRIL)
WO2003055979A3 (en) ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS
CY1115003T1 (el) Θεραπευτικη χρηση των αντισωματων αντι-cs1
AR029624A1 (es) Anticuerpos o fragmentos de anticuerpos anti-idiotipicos recombinantes y composicion farmaceutica que los contiene
FR2804027B1 (fr) Utilisation d'anticorps monoclonaux anti-ferritines dans le traitement de certains cancers
ATE286914T1 (de) Verwendung von blockierenden anti-tsh-rezeptor- antikörpern bei der therapie von hyperthyreosen sowie monoklonale antikörper für eine solche verwendung

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: FACET BIOTECH CORPORATION (US)

Free format text: TRANSFERIDO DE: PDL BIOPHARMA, INC.

B25D Requested change of name of applicant approved

Owner name: ABBOTT BIOTHERAPEUTICS CORP. (US)

Free format text: NOME ALTERADO DE: FACET BIOTECH CORPORATION

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: ABBVIE BIOTHERAPEUTICS INC (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/02/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/05/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF